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INTRODUCTION 
 
Cancer is a major public health problem worldwide, with colon 
cancer ranking as the third most common cause of cancer 
mortality in the United States.  There are an estimated 96,830 
new cases and 50,310 deaths in 2014 due to colon 
cancer[1](Figure1). However, the molecular mechanism of colon 
tumorigenesis is poorly understood and the prognosis is very 
bad due to multiple drug resistance.  Therefore, there is urgent 
need to identify a novel therapeutic target.  Recently, LRH1, an 
orphan nuclear receptor, has been identified as a key regulator 
for intestinal function with implications for common intestinal 
diseases including colorectal cancer[2]. We hypothesize that 
LRH1 may be a central signaling molecule during the 
progression of colon cancer.  To investigate this, we used the 
lentiviral expression system to establish stable cell lines with 
over-expressed LRH1 and examined that LRH1 can promote 
cell proliferation with MTT analysis.  We will also detect the 
LRH1 downstream proteins’ expression level by Western blot 
analysis.  
RESULTS 
 
1. Establishment of colon cancer cell line with 
constitutive LRH-1 overexpression  
We did transfection on 3 colon cancer cell lines 
(CaCo-2, LS-180 and SK-CO-1) with LRH-1 
plasmid, and the results showed no or very weak 
LRH-1 protein expression.  
 
2. LRH-1 upregulates downstream target 
proteins PCNA (in liver cancer), cyclin D1/E1, 
ERα and Calpain1 (in pancreatic cancer) [3,4] 
We examined the potential mechanisms of LRH-1 
involvement in liver and pancreatic cancer by 
measuring its downstream target genes. Western blot 
analysis revealed that PCNA , cyclin D1 and cyclin 
E1 (full-length [FL] and truncated T1/T2 isoforms) 
were upregulated by LRH-1 in stable PC cells, 
Cyclin E is converted to T1/T2 by calpain1 through 
post-translational processing. LRH1-mediated 
cyclin E T1/T2 overexpression was attributed to 
upregulation of  ERα-Calpain1 signaling (Fig. 2). 
 
3. LRH-1 promotes liver and pancreatic cancer 
cell proliferation 
LRH-1 overexpression resulted in a significant 
increase in liver and pancreatic cancer cell 
proliferation compared with the control (Fig. 3).  
 
4. Tumorigenicity of LRH-1 in vivo 
In vitro observations suggest that LRH-1 expression 
is important for pancreatic cancer cell proliferation. 
Therefore, we explored its oncogenic role in vivo 
using a murine subcutaneous (s.c.) model (Fig. 5). 
We measured the resulting tumor growth in the 
immune deficient mice after injection of parental 
and LRH-1-transfected pancreatic cancer cells. 
Following introduction and expression of LRH-1, 
Capan-1 cells generated significantly enhanced 
subcutaneous tumor growth characterized by a 
significantly increased tumor weight compared to 
vectors. 
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FUTURE WORK 
•Establish other stable pancreatic and colon cancer 
cell lines overexpressing LRH-1 using lentiviral 
expression system. 
•Confirm the expression of LRH-1 by Western blot 
and RT-PCR. 
 
•Examine the expression levels of cancer stem cell 
markers: 
     CD24 / CD44 / ESA / c-MET / ALDH 
•Determine if LRH-1 overexpression enhances 
migration, invasion and sphere formation of 
pancreatic and colon cancer cells.  
 
REFERENCES 
[1] Rebecca Siegel, Jiemin Ma, Zhaohui Zou, et al.  Cancer 
Statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.  
[2] K. Schoonjans, L. Dubuquoy, J. Mebis, E. Fayard, O. 
Wendling, C. Haby, K. Geboes, J. Auwerx,  Liver receptor 
homolog 1 contributes to intestinal tumor formation through 
effects on cell cycle and inflammation, Proc. Nat. Acad. Sci. 
USA 2005;102:2058–2062. 
[3]  Lin Q, Aihara A, Chung W, Li Y, Huang Z, Chen X, 
Weng S, Carlson R, Shaikh Z, Wands J, Dong X. LRH1 
promotes pancreatic cancer metastasis. Cancer Lett. in press 
[4]  Lin Q, Aihara A, Chung W, Li Y, Huang Z, Chen X, 
Weng S, Carlson R, Wands J, Dong X. LRH1 as a driving 
factor in pancreatic cancer growth. Cancer Lett. 2014;345:85-
90. Epub 2013 Dec 11. 
 
 
METHODS AND  
MATERIALS 
 
LRH-1 overexpressed stable cell lines 
 
Stable liver and pancreatic cancer cells with constitutive 
expression of LRH-1 were established by using the 
Lentiviral Expression system (GeneCopoeia). Sk-Hep-1, 
AsPC-1 and Capan-1 cells were infected with lentiviral 
particles. Twenty-four hours after infection, cells were 
incubated with corresponding media for 24 h, then treated 
with 0.8 μg/mL (for Sk-Hep-1), 8 μg/mL (for Capan-1) and 
3 μg/mL (for AsPC-1) puromycin overtime to eliminate un-
infected cells and thus yield mass populations of 
puromycin-resistant cells expressing the LRH-1. The LRH-
1 protein level in stable pancreatic cancer cell lines was 
confirmed by Western blot.  
 
 
 
 
Western Blot Analysis 
 
Cell lysates were treated with ConA-sepharose beads overnight 
followed by centrifugation to remove cadherin-bound β-catenin. 
Total Cell lysates and non-membrane bound cell lysates were 
separated by SDS PAGE and transferred to nitrocellulose 
membranes. Western blot analysis was performed using primary 
antibodies against LRH1 (Abcam, ab125034), c-Myc (Cell signaling 
Technology, #5605), cyclin D1 (Santa Cruz, sc-8396), cyclin E1 
(Santa Cruz, sc-247), β-catenin (Cell signaling Technology, #9562), 
calpain1 (Santa Cruz, sc-7531), estrogen receptor alpha (ERα) (Santa 
Cruz, sc-7207), PCNA (Santa Cruz, sc-7907). Protein bands were 
visualized by IRDye® 680RD Infrared Dye and IRDye® 800CW 
Infrared Dye and exposed on Odyssey image system  (LI-COR).  
 
 
 
 
MTT Assay 
 
Liver and pancreatic cancer cells (vectors vs. LRH1 
overexpressing Sk-Hep-1, Capan-1 and AsPC-1) 
(1.7×104 cells per well) were seeded in 24 well plates 
and cultured for 4 days. Cells were incubated with 
MTT solution (Sigma-Aldrich) in medium (10% v/v) at 
37 °C for 3 h. Then 200µl DMSO was added. Plates 
were analyzed daily using a plate reader at a 
wavelength of 570 and 690 nm, respectively. The 
background absorbance of multi-well plates measured 
at 690 nm was subtracted from the measurement at 570 
nm.  
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Fig.5. LRH-1 promoted pancreatic tumor growth in nude 
mice. The subcutaneous tumor model was established by 
inoculation of Capan-1 cells transfected with LRH-1 and 
Vector control. Compared to vectors, LRH-1 overexpression 
cells produced larger size tumors (paired t test, 2 tailed, 
**p<0.01).  
Fig.3. Growth curves of liver and pancreatic cancer cells with 
LRH-1 overexpression. Accelerated cell growth was observed in 
LRH-1 overexpressed Sk-Hep-1 (Liver cancer), Capan-1 and 
AsPC-1(Pancreatic cancer) cells than in controls (Student t test, 
2-tailed, *p<0.05). 
Fig.2. LRH-1 upregulated downstream target genes in liver 
cancer and pancreatic cancer cells.  
Fig.4. LRH-1 promote cell proliferation by inducing Cyclin D1 and E1 through β-catenin/Tcf-4 signaling 
pathway. 
FIGURES  
Fig.1. Estimated new cancer cases and deaths by sex, United States, 2014 
